Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

Condition(s) studied

Investigational drug(s) / intervention(s)

Axicabtagene Ciloleucel: Axicabtagene Ciloleucel at 2.0×10\^6/Kg

Study summary

The goal of this clinical trial is to learn if Axicabtagene Ciloleucel (axi-cel) works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of axi-cel treatment. The main questions it aims to answer are:

* Does axi-cel treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment?
* What medical problems do participants have when receiving axi-cel treatment?

In this investigator-initiated, single-arm clinical trial, participants will:

* Receive atezolizumab treatment at 2.0×10\^6 cells/Kg as a one-time therapy.
* Visit the clinic as instructed for checkups and tests.

Eligibility

Primary outcome measure(s)

• one year PFS — From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months

Trial sites (1)

On this site

More Zhengzhou University trials in China

Other trials for the same condition